Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

被引:325
作者
Landolfi, Raffaele
Di Gennaro, Leonardo
Barbui, Tiziano
De Stefano, Valerio
Finazzi, Guido
Marfisi, RosaMaria
Tognoni, Gianni
Marchioli, Roberto
机构
[1] Catholic Univ, Sch Med, Inst Internal Med & Geriatr, Haemostasis Res Ctr, I-00168 Rome, Italy
[2] Inst Ricovero & Cura & Carattera Sci Oasi Maria S, Troina, Italy
[3] Osped Riuniti Bergamo, Bergamo, Italy
[4] Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
关键词
D O I
10.1182/blood-2006-08-042515
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In polycythemia vera, vascular risk assessment is based on age and thrombotic history, while the role of other potential predictors of this risk is still uncertain. Thus, we exploited the large database collected by the observational study of the European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) to investigate the association of hematologic variables and cardiovascular risk factors with the thrombotic risk. Among 1638 polycythemic patients followed for 2.7 +/- 1.3 years, there were 205 thromboses. Subjects with hypertension had a mild nonsignificant increase in the risk of arterial thrombosis, while this risk was significantly increased by smoking (hazard ratio [HR], 1.90; 95% confidence interval [CI], 1.15-3.14; P=.012). The time-dependent analysis adjusted for potential confounders showed that patients with a white blood cell count above 15 x 10(9)/L, compared with those with a white blood cell count below 10 x 109/L, had a significant increase in the risk of thrombosis (HR, 1.71; 95% Cl, 1.10-2.65; P =.017), mainly deriving from an increased risk of myocardial infarction (HR, 2.84; 95% Cl, 1.25-6.46; P =.013). Thus, leukocyte count may help in defining the vascular risk of polycythemic subjects.
引用
收藏
页码:2446 / 2452
页数:7
相关论文
共 21 条
[1]  
CHIEVITZ E, 1962, ACTA MED SCAND, V172, P513
[2]   Leukocytosis and ischemic vascular disease morbidity and mortality - Is it time to intervene? [J].
Coller, BS .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (04) :658-670
[3]  
Falanga A, 2000, BLOOD, V96, P4261
[4]   Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera [J].
Falanga, A ;
Marchetti, M ;
Vignoli, A ;
Balducci, D ;
Barbui, T .
EXPERIMENTAL HEMATOLOGY, 2005, 33 (05) :523-530
[5]   Leukocyte count as an independent predictor of recurrent ischemic events [J].
Grau, AJ ;
Boddy, AW ;
Dukovic, DA ;
Buggle, F ;
Lichy, C ;
Brandt, T ;
Hacke, W .
STROKE, 2004, 35 (05) :1147-1152
[6]  
LANDOLFI R, 1992, BLOOD, V80, P1965
[7]   Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: Current insights and rationale for future studies [J].
Landolfi, R ;
Di Gennaro, L ;
Novarese, L ;
Patrono, C .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (03) :251-259
[8]  
Landolfi R, 1997, THROMB HAEMOSTASIS, V78, P617
[9]   Efficacy and safety of low-dose aspirin in polycythemia vera [J].
Landolfi, R ;
Marchioli, R ;
Kutti, J ;
Gisslinger, H ;
Tognoni, G ;
Patrono, C ;
Barbui, T ;
Landolfi, R ;
Marchioli, R ;
Kutti, J ;
Gisslinger, H ;
Tognoni, G ;
Patrono, C ;
Barbui, T ;
Gisslinger, H ;
Barbui, T ;
Finazzi, G ;
Pusterla, S ;
Falanga, A ;
Galli, M ;
Kutti, J ;
Wadenvik, H ;
Gastl, G ;
Ludescher, C ;
Lutz, D ;
Girschikofsky, M ;
Michlmayr, G ;
Rechberger, E ;
Niessner, H ;
Ivansich, E ;
Rain, JD ;
Chommienne-Thomas, C ;
Hehlmann, R ;
Engelich, G ;
Kohne, E ;
Kramer, A ;
Christakis, JI ;
Papaioannou, M ;
Gerotziafas, G ;
O'Donnell, R ;
Bennett, M ;
Lugassy, G ;
Ellis, M ;
Eldor, A ;
Naparstek, E ;
Marilus, R ;
Leoni, P ;
Rupoli, S ;
Scortechini, AR ;
Agostini, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (02) :114-124
[10]   Diagnosis and therapy of polycythemia vera [J].
Lengfelder, E ;
Merx, K ;
Hehlmann, R .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (03) :267-275